chrisvoncsefalvay/vaers-outcomes huggingface dataset:
With in 30 minutes of receiving my 1st does of the vaccine my mouth started burning like it was on fire and turned white; This is a spontaneous report from a contactable consumer (patient). A 57-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: FC3183), via an unspecified route of administration, administered in Arm Right on 03Sep2021 16:30 at the age of 57-year-old as dose 1, single for covid-19 immunisation from pharmacy or drug store. Medical history included Sjogren's syndrome, Raynaud's, Chilblains, chronic venous insufficiency, osteoarthritis and allergies to many antibiotics, tetanus shot. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with covid prior to vaccination and patient was not tested for COVID-19 post vaccination. Concomitant medication included vitamin b complex (VITAMIN B COMPLEX) and clonazepam (CLONAZEPAM) taken for an unspecified indication, start and stop date were not reported. The patient previously took antibiotics and experienced drug hypersensitivity, tetanus toxoid for immunisation and experienced allergy to vaccine.  On 03Sep2021 17:00 (within 30 minutes of receiving first does of the vaccine) patient experienced mouth started burning like it was on fire and turned white which ae resulted in doctor or other healthcare professional office/clinic visit, disability or permanent damage. The burning sensation has not stopped. Patient take a numbing mouthwash for the event that really doesnt help much. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Just got my second shingle shot yesterday. I was sore for a day or so; This case was reported by a consumer via interactive digital and described the occurrence of pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.  On 15th July 2021, the patient received the 2nd dose of Shingles vaccine. In July 2021, less than a day after receiving Shingles vaccine, the patient experienced pain. On an unknown date, the outcome of the pain was recovered/resolved.   It was unknown if the reporter considered the pain to be related to Shingles vaccine.  Additional details were reported as follows: The age at vaccination was not reported. The patient received Shingrix and was sore for a day. The patient was glad he/she received it.
A nurse reported the occurrence of an injection site reaction in an 18-month-old male who received diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix).  The medical history, concurrent conditions, and concurrent medications were not specified.  On 05/28/2002, the vaccinee received his fourth injection of Infanrix (lot DTPA542A2; expiration date 09/24/2003).  On the same date, he also received an injection of inactivated poliomyelitis virus vaccine (IPOL) into the opposite arm.  That evening, he began to develop an injection site reaction characterized by redness and local swelling that progressively got worse.  The swelling extended to include half of his forearm.  The vaccinee was seen by a physician.  The reporter stated that the events were probably related to Infanrix administration.  As of 05/30/2002, the events were "worse".
Patient tolerated well no adverse reaction, dose was given after vial was in fridge for 30 days.
Low grade fever, 3 events with in 1 hour, eyes rolled back, hands cloded up, pt went back, shaking.
Information has been received from a nurse concerning a 14 year old patient with allergy to unspecified medication who on 12-DEC-1999 was vaccinated with the first dose of VARIVAX (Oka/Merck). On 18-JUN-2008( also reported on 18-AUG-2008) the patient had a full blown chicken pox. On an unspecified date the patient recovered from a full blown chicken pox. The patient sought medical attention and saw the physician. Additional information has been requested.
03/31/09 Dtap given, 04/01/09 Pt. had axillary temp of 103, 04/02/09 Pt. had 2-3cm redness at injection site
Went to my doctor thinking it was a very very bad sinus infection. My doctor didn't think it was with the way my headaches were. It hurt on the back right and above the right ear. It hurt to touch. My tongue is not functjioning now.  I had to get a MRI because they thought it could of been a mini stroke. MRI came back negative the doctors told me Bell Palsy.  They advise me not to get my second dose on 2/3/21.
This spontaneous report was received from a vaccine coordinator concerning an unspecified patient of an unknown age and gender. The patient's concurrent conditions, medical history, historical drugs and concomitant therapies were not reported. On an unknown date, the patient might have received one improperly stored dose of PNEUMOVAX23 lot numbers N003993, N004564, expiration dates 20-OCT-2018, 22-OCT-2018 respectively (dose and route were not reported), ROTATEQ orally, lot number M019691, expiration date 02-NOV-2017 (dose was not reported), GARDASIL 9 lot numbers M031557, M041990, expiration dates 07-APR-2019, 28-JUN-2019 respectively (dose and route was not reported) or LIQUID PEDVAXHIB lot numbers M020101, K016964, expiration dates 07-MAR-2019, 16-JUL-2017 respectively (dose and route were not reported) all for prophylaxis. The reporter was not sure about which of the vaccines was received for the patient. The temperature involve was -0.9 Celsius Degrees for 3 hours and 30 minutes. There was no temperature excursion, and a data logger was involved. No adverse effects reported. Additional information has been requested.
muscle aches for 24 hours/body aches for 24 hours; chills for 24 hours; This spontaneous case was reported by a patient and describes the occurrence of MYALGIA (muscle aches for 24 hours/body aches for 24 hours) and CHILLS (chills for 24 hours) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 021F21B, 0441321A and 021C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Dec-2021, the patient experienced MYALGIA (muscle aches for 24 hours/body aches for 24 hours) and CHILLS (chills for 24 hours). On 05-Dec-2021, MYALGIA (muscle aches for 24 hours/body aches for 24 hours) and CHILLS (chills for 24 hours) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment information was provided.   This case was linked to MOD-2021-406090 (Patient Link).
Sore throat came first, followed by fatigue and a low grade (99.5) fever. The sore throat still hurts as of 9/30/15. Fever is gone, fatigue still present.
From initial information received on 4/21/04 from a health care professional regarding an adverse event occurring in the USA, it was reported that a 28 year old female patient received a pose-exposure IMOVAX RABIES vaccination, lot number X0581, administered IM in the left deltoid on 4/20/04 at3:45 PM. The dose number was not reported. The same day at 6:00 PM, the patient experienced pain and numbness in the left arm without loss of movement or use of her left upper extremity. She also experienced sweats, body aches, and a dry mouth. The health department is referring the patient to a physician for evaluation and administration of second post-exposure dose. Per the patient the symptoms were resolving as of 4/21/04. Additional information was received on 4/23/04 from a telephone contact with the initial reporter. She stated that since the patient's symptoms were resolving, no physician evaluation or treatment was obtained. The patient's employer, a veterinarian, is having her get a titer done to determine immunity. From additional information received on 5/18/04 from the initial reporter, the patient had still not had a titer drawn as of 5/11/04, but still plans to do so. They will notify the company when the results are obtained. Reportedly, the patient recovered from the events.
This spontaneous report as received from a female consumer of unknown age with drug reactions/allergies to penicillin and no pertinent medical history refers to herself. On 18-OCT-2013, the patient was vaccinated with a dose of ZOSTAVAX (dose, route, lot number not reported). There was no concomitant medication. On 19-OCT-2013, the patient experienced rash at the injection site described as red, raised and about five inches long. It was itchy and warm to the touch, with a knot at the injection site. However, there were no blisters. There was no treatment given for adverse events. No laboratory tests were performed. The patient's outcome of adverse events was unknown. The patient did not seek medical attention. The relatedness between adverse events and ZOSTAVAX was not reported. Additional information has been requested.
Currently suffering from symptoms indicative of brain damage, namely new anxiety, mood changes, some occasional headaches, mild brain fog, and insomnia (have not slept for more than 4-5 hours injection date.  Also have messed up sense of temperature, as well as occasional aches.  Also had soreness in jabbed arm as well as inflammation in said arm.
elevated temp, flushed face, shaking, c/o being cold, shivering- assessed by physician and transferred to ER
Nausea, chills, fever lasting 3 days.  Joint Pain and malaise for one week, believed to be an RA flare from vaccine
Post-injection, patient felt scratchy throat, had inability to speak, and was tachycardic.   Rapid response team was called.
After the booster shot, I did not feel any issue for a day or two.  However, from 2nd or 3rd day onwards I started having rashes on my body and it is continuing till date (however the frequency and the amount of rashes reduced compared to the beginning).  I am taking Zyrtec and that is helping with rashes.
Moderna COVID-19 Vaccine EUA  Primary complaint is a severe migraine. Also experiencing fatigue, alternating chills/heat with a temperature of 99.3 degrees & body aches.
Patient arm became sore and red.  It stretched  down below the elbow.  Lasted two or three days and resolved
Left upper arm erythema 11.5 cm x 12cm at IPV site with vesicles 2cm x 1cm. Ecchymosis 2cm x 1.5cm at DTaP site (itches) tight red, warm.
Noticed red rash to arm 12 days after injection. No pruritus. Area slightly warm to touch but no pain Could have been there earlier but never thought to examine the site due to the absence of pain after day 2 and lack of pruritus.
body ache; 99°F fever; Chills; headache; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (body ache), HEADACHE (headache), FATIGUE (fatigue), PYREXIA (99°F fever) and CHILLS (Chills) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concomitant products included SUMATRIPTAN SUCCINATE (IMITREX DF) for an unknown indication.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Jan-2021, the patient experienced HEADACHE (headache) and FATIGUE (fatigue). On 13-Jan-2021, the patient experienced MYALGIA (body ache), PYREXIA (99°F fever) and CHILLS (Chills). On 13-Jan-2021, FATIGUE (fatigue) had resolved. On 14-Jan-2021, MYALGIA (body ache), HEADACHE (headache), PYREXIA (99°F fever) and CHILLS (Chills) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous report was received from a medical assistant and refers to an unspecified patient of unknown demographics. No information regarding the patient's pertinent medical history, concomitant medications and drug reactions or allergies was provided. On 15-MAY-2017, the patient was vaccinated with an expired dose of GARDASIL injection (lot# K016966 with expiration date on 10-MAY-2017; dose, route of administration and anatomical location were not reported). No adverse effect was reported. No product quality complaint (PQC) was involved. Additional information has been requested.
pt recvd vax;run fever 1 1/2 hr later;to MD 17dec w/ fever of 104.8;blood work run to r/o infect;mom said no infect;pt having allergic rxn;tx w/ motrin & apap;rechecked by MD 19dec;blood work WNL;no fever 20dec;
Received dose #2. Within 10 minutes, developed metallic taste. 4 hours later severe nausea and vomiting. Began alternating Tylenol and Ibuprofen 800mg. 6 hours to the following day- severe headaches, chills, body aches, all over joint pain. Around midnight on 1/6/21 pain in the arm that radiated up her neck. 1/7- fever of 101. Small rash around injection site and slightly down arm. Stiff neck and arm pain.
First dose administered 11Mar2021,Second dose administered 16Apr2021; bone pain; second dose of vaccine administered after excursion; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (second dose of vaccine administered after excursion), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose administered 11Mar2021,Second dose administered 16Apr2021) and BONE PAIN (bone pain) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No medical history was provided by reporter.  No concomitant medication reported.     On 16-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (second dose of vaccine administered after excursion). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose administered 11Mar2021,Second dose administered 16Apr2021) and BONE PAIN (bone pain). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (second dose of vaccine administered after excursion), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose administered 11Mar2021,Second dose administered 16Apr2021) and BONE PAIN (bone pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.    Concomitant medication use was unknown No treatment medication reported.   This case was linked to MOD-2021-250480 (Patient Link).
It was discovered the vaccine received was stored in a freezer longer than recommended by the manufacturer. Per the manufacturer, since the potency of the vaccine cannot be determined, it's unclear of the level of immunity this dose was expected to deliver. After consulting with our immunization experts, and with the vaccine manufacturer, it's recommended to repeat the dose to ensure full protection.
COULD NOT WALK; PAIN IN EAR; PAIN IN ABDOMEN; PAIN IN NECK; DIFFICULTY URINATING; PAIN IN GROIN AREA; PINCHING SENSATION; PAIN IN CHEST; PAIN IN UPPER BACK; BURNING SENSATION WHEN URINATING; HEAVY LEFT SHOULDER; TINGLING SENSATION; THROBBING HEADACHE/ HEADACHE THAT DID NOT GO AWAY; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 27-OCT-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 27-OCT-2021, the patient experienced could not walk. On 27-OCT-2021, the patient experienced pain in ear. On 27-OCT-2021, the patient experienced pain in abdomen. On 27-OCT-2021, the patient experienced pain in neck. On 27-OCT-2021, the patient experienced difficulty urinating. On 27-OCT-2021, the patient experienced pain in groin area. On 27-OCT-2021, the patient experienced pinching sensation. On 27-OCT-2021, the patient experienced pain in chest. On 27-OCT-2021, the patient experienced pain in upper back. On 27-OCT-2021, the patient experienced burning sensation when urinating. On 27-OCT-2021, the patient experienced heavy left shoulder. On 27-OCT-2021, the patient experienced tingling sensation. On 27-OCT-2021, the patient experienced throbbing headache/ headache that did not go away. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from tingling sensation, could not walk, pain in ear, pain in abdomen, pain in neck, difficulty urinating, pain in groin area, pinching sensation, pain in chest, pain in upper back, burning sensation when urinating, throbbing headache/ headache that did not go away, and heavy left shoulder. This report was non-serious.
Mild hives off and on on both arms and some times on torso, mostly in the mornings and self resolves in 2-3 hours without medicine.  Also.,  partial lip edema twice noticed in the morning  once on Dec31 and second time on January 4th.  Both times lip edema resolved with in 4-5 hrs. on its own without any medication.  Mild hives continue to show on arms and hand sporadically and self resolve with in few hours with any anti-histamine.
Experienced syncopal episode while seated in chair at Exit station after receiving first dose of Pfizer COVID 19 Vaccine.  Patient was found to be pale, diaphroretic and + LOC.  Was transferred to cot and surrounded by privacy screen. 18:10 118/60 HR 70 95% SpO2.  Cold packs were provided to back of neck and forehead. In addition water and snack were provided when return to full consciousness was achieved.   Was observed for an additional 30 mins.  Full resolution of symptoms.  18:30 140/88 HR 60 98% SpO2.  No further incident occurred and patient was released to significant other and told to call 911 if symptoms worsened.
Patient described shortness of breath, and felt not well. Alerted staff, and administered her own Epi pen at 12:12.
August 12, 2021 sudden large increase in visual floaters. Oct 1, 2021 exceptional increase in visual floaters followed by decreased clouded vision left eye. Oct 2, 2021 sudden onset eyeball pain left eye with listed visual decline and floaters. Oct 2, 2021 Diagnosis Posterior Vitreous Detachment with increased vitreous debris/Vitritis left eye. Referral to specialist Oct 6, 2021 Eye specialist verified unusual viritis left eye and referred to retinal specialist. Oct 7, 2021 Retinal specialist confirmed vitritis but also asked many autoimmune questions and ordered many such tests as this condition is unusual in a person of my age.
Pt recovered severe vomiting and diarrhea on 12/11/08 at appx 12AM x 4 hours. No fever or headache. Did not seek medical attention.
She also passed out going to the bathroom twice.; Felt hot; Clammy; Feels very weak; Pain in left arm,; Difficulty moving left arm; Fever; chills; Nauseous; This spontaneous case was reported by a consumer and describes the occurrence of LOSS OF CONSCIOUSNESS (She also passed out going to the bathroom twice.) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No reported medical history).   On 13-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Apr-2021, the patient experienced LOSS OF CONSCIOUSNESS (She also passed out going to the bathroom twice.) (seriousness criterion medically significant), FEELING HOT (Felt hot), COLD SWEAT (Clammy), ASTHENIA (Feels very weak), PAIN IN EXTREMITY (Pain in left arm,), MOBILITY DECREASED (Difficulty moving left arm), PYREXIA (Fever), CHILLS (chills) and NAUSEA (Nauseous). At the time of the report, LOSS OF CONSCIOUSNESS (She also passed out going to the bathroom twice.), FEELING HOT (Felt hot), COLD SWEAT (Clammy), ASTHENIA (Feels very weak), PAIN IN EXTREMITY (Pain in left arm,), MOBILITY DECREASED (Difficulty moving left arm), PYREXIA (Fever), CHILLS (chills) and NAUSEA (Nauseous) outcome was unknown.            Treatment medication included acetaminophen.  Action taken with m-RNA1273 in response to events is consider as not applicable.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
rash that consist of "little tiny bumps"; little tiny bumps; Rash is Warm to Touch; Became a litle redder; This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 58-year-old male patient who received Herpes zoster (Shingrix) (batch number 3HX44, expiry date 15th November 2021) for prophylaxis.   On 2nd August 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 7th August 2019, 5 days after receiving Shingrix, the patient experienced rash, swelling, skin warm and erythema. On an unknown date, the outcome of the rash, skin warm and erythema were not recovered/not resolved and the outcome of the swelling was unknown.   It was unknown if the reporter considered the rash, swelling, skin warm and erythema to be related to Shingrix.  Additional information received were as follows: The patient received Shingrix on right deltoid. a day before the reporting date, the patient presented to the pharmacist with a rash that consisted of little tiny bumps surrounding the injection site.  The reporting pharmacist reported that the patient's rash was warm to touch and had mostly remained the same but became a little redder. The onset of rash was eporting pharmacist reports the patient's rash is warm to touch and has mostly remained the same but became a little redder.  The onset of rash was unknown.
On 6/13/01, severe headache then a high fever with chills and rash from head to toe. Seen by MD and dx'd with viral infection vs allergic reaction.